Jennifer Wu

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. doi request reprint Chronic thalidomide and chemoembolization for hepatocellular carcinoma
    Jennifer Wu
    New York University School of Medicine, New York, New York, USA
    Oncologist 19:1229-30. 2014
  2. pmc Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis
    Holly Hagan
    College of Nursing, New York University, New York, USA
    Syst Rev 3:31. 2014
  3. pmc Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences
    Jennifer Ng
    Department of Medicine, New York University Langone Medical Center, New York, United State
    Hepat Mon 12:e7635. 2012
  4. ncbi request reprint Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer
    Jennifer Wu
    Divisions of Hematology and Medical Oncology, Department of Medicine, NYU Cancer Institute, NYU School of Medicine, 550 First Ave, BCD 556, New York, NY 1006, USA
    Anticancer Res 32:939-45. 2012
  5. doi request reprint Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Jennifer Wu
    Department of Medical Oncology, NYU School of Medicine, New York, NY, USA
    Invest New Drugs 28:670-6. 2010
  6. pmc Targeting insulin-like growth factor axis in hepatocellular carcinoma
    Jennifer Wu
    Division of Hematology and Medical Oncology, NYU Cancer Institute, NYU School of Medicine, New York, NY 10016, USA
    J Hematol Oncol 4:30. 2011
  7. ncbi request reprint Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact
    Jennifer Wu
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:936-43. 2012
  8. ncbi request reprint Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration
    Sasha O Joseph
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:1021-30, 1035. 2012
  9. pmc Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
    Ping Gu
    Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USA
    Int J Hepatol 2012:131659. 2012
  10. pmc Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C Pavlick
    New York University School of Medicine, New York University Cancer Institute, New York, NY, USA
    Cancer Chemother Pharmacol 64:803-10. 2009

Collaborators

Detail Information

Publications10

  1. doi request reprint Chronic thalidomide and chemoembolization for hepatocellular carcinoma
    Jennifer Wu
    New York University School of Medicine, New York, New York, USA
    Oncologist 19:1229-30. 2014
    ..We conducted a phase I trial to evaluate the efficacy and toxicity of thalidomide when combined with TACE in patients with advanced HCC...
  2. pmc Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis
    Holly Hagan
    College of Nursing, New York University, New York, USA
    Syst Rev 3:31. 2014
    ..There is a need for systematic reviews and meta-analyses to synthesize the epidemiology, prevention and methods to control HCV infection in this population...
  3. pmc Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences
    Jennifer Ng
    Department of Medicine, New York University Langone Medical Center, New York, United State
    Hepat Mon 12:e7635. 2012
    ....
  4. ncbi request reprint Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer
    Jennifer Wu
    Divisions of Hematology and Medical Oncology, Department of Medicine, NYU Cancer Institute, NYU School of Medicine, 550 First Ave, BCD 556, New York, NY 1006, USA
    Anticancer Res 32:939-45. 2012
    ..We explored its tolerance and preliminary efficacy when given together with cisplatin in a phase I/II study preferentially enrolling gastric cancer patients...
  5. doi request reprint Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Jennifer Wu
    Department of Medical Oncology, NYU School of Medicine, New York, NY, USA
    Invest New Drugs 28:670-6. 2010
    ..Darinaparsin is a novel organic arsenic that reaches higher intracellular concentration with decreased toxicity compared to inorganic arsenic. We conducted a multi-center phase II study with darinaparsin in patients with advanced HCC...
  6. pmc Targeting insulin-like growth factor axis in hepatocellular carcinoma
    Jennifer Wu
    Division of Hematology and Medical Oncology, NYU Cancer Institute, NYU School of Medicine, New York, NY 10016, USA
    J Hematol Oncol 4:30. 2011
    ..IGF axis is increasingly recognized as one of the most relevant pathways in HCC and agents targeting this axis can potentially play an important role in the treatment of HCC...
  7. ncbi request reprint Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact
    Jennifer Wu
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:936-43. 2012
    ....
  8. ncbi request reprint Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration
    Sasha O Joseph
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:1021-30, 1035. 2012
    ..Taken together, these two types of advance illustrate the remarkable overall effect of modern cancer therapeutics' focus on tumor biology and tumor immunology...
  9. pmc Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
    Ping Gu
    Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USA
    Int J Hepatol 2012:131659. 2012
    ..Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis...
  10. pmc Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C Pavlick
    New York University School of Medicine, New York University Cancer Institute, New York, NY, USA
    Cancer Chemother Pharmacol 64:803-10. 2009
    ..We designed a phase I study to achieve tolerable doses and schedules of bryo and cisplatin in combination and in this sequence...